Trial Profile
A Phase 3, Randomized, Double-blind Clinical Study to Evaluate the Long-term Safety and Efficacy of MK-7264 in Japanese Adult Participants With Refractory or Unexplained Chronic Cough
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 16 May 2022
Price :
$35
*
At a glance
- Drugs Gefapixant (Primary)
- Indications Cough
- Focus Adverse reactions; Registrational
- Sponsors Merck Sharp & Dohme
- 16 Oct 2020 Status changed from active, no longer recruiting to completed.
- 06 May 2020 Planned End Date changed from 6 Oct 2020 to 30 Sep 2020.
- 06 May 2020 Planned primary completion date changed from 6 Oct 2020 to 30 Sep 2020.